Urine complement analysis implies complement activation is involved in membranous nephropathy
In patients with MN, abnormal levels of complement components in urine are commonly observed. Currently, the use of complement inhibitors has brought new hope for the treatment of MN. The factor B inhibitor LNP023 and the factor D inhibitor BCX9930 are undergoing clinical trials for the treatment of MN. Our study indicates that complement abnormalities could serve as clinical biomarkers for tracking the progression of MN, predicting clinical remission, and guiding targeted complement therapy for those affected.
Authors
- Guisen Li (ORCID: https://orcid.org/0000-0003-1970-9979)
- Yi Li (ORCID: https://orcid.org/0000-0001-5130-6382)
- Yingxue Xu (ORCID: https://orcid.org/0000-0002-9657-3107)
- Yong Zhang (ORCID: https://orcid.org/0000-0003-1436-5951)
Institutions
- University of Electronic Science and Technology of China (CN)
- Sichuan University (CN)
- Affiliated Hospital of Southwest Medical University (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-02-13
- DOI
- https://doi.org/10.3389/fmed.2025.1515928
- Citations
- 2
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 2.86
Funders
- National Natural Science Foundation of China
- Department of Science and Technology of Sichuan Province